Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Schroeder

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Molecular Cancer Therapeutics|September 27, 2017
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in GlioblastomaSani H Kizilbash, Shiv K Gupta, Kenneth Chang, et al.
The Lancet. Haematology|December 31, 2021
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trialRobert Zeiser, Gérard Socié, Mark A Schroeder, et al.
American Journal of Hematology|August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study resultsJorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Leukemia & Lymphoma|January 20, 2021
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromesEric Huselton, Michael P Rettig, Theresa Fletcher, et al.
Blood|March 16, 2017
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graftMark A Schroeder, Michael P Rettig, Sandra Lopez, et al.
Cancer Medicine|October 24, 2017
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimenAlaa M Ali, Daniel Weisel, Feng Gao, et al.
Neuro-Oncology|August 22, 2019
Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clonesBen Yi Tew, Christophe Legendre, Mark A Schroeder, et al.
Journal of the National Cancer Institute|May 23, 2018
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic VirotherapyCheyne Kurokawa, Ianko D Iankov, S Keith Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in GlioblastomaJenny L Pokorny, David Calligaris, Shiv K Gupta, et al.
Blood|March 19, 2025
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCTZachariah DeFilipp, Haesook T Kim, Laura W Knight, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Molecular Cancer Therapeutics|September 27, 2017
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in GlioblastomaSani H Kizilbash, Shiv K Gupta, Kenneth Chang, et al.
The Lancet. Haematology|December 31, 2021
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trialRobert Zeiser, Gérard Socié, Mark A Schroeder, et al.
American Journal of Hematology|August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study resultsJorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Leukemia & Lymphoma|January 20, 2021
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromesEric Huselton, Michael P Rettig, Theresa Fletcher, et al.
Blood|March 16, 2017
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graftMark A Schroeder, Michael P Rettig, Sandra Lopez, et al.
Cancer Medicine|October 24, 2017
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimenAlaa M Ali, Daniel Weisel, Feng Gao, et al.
Neuro-Oncology|August 22, 2019
Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clonesBen Yi Tew, Christophe Legendre, Mark A Schroeder, et al.
Journal of the National Cancer Institute|May 23, 2018
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic VirotherapyCheyne Kurokawa, Ianko D Iankov, S Keith Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in GlioblastomaJenny L Pokorny, David Calligaris, Shiv K Gupta, et al.
Blood|March 19, 2025
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCTZachariah DeFilipp, Haesook T Kim, Laura W Knight, et al.
Pageof 11